Cytokinetics’ aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist’s Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead’s Bixlenvo is cleared as the smallest single tablet regimen for adults with HIV who are virologically suppressed, AstraZeneca and Ionis’ eplontersen misses its primary endpoint in the Phase 3 CARDIO-TTRansform trial in transthyretin amyloid cardiomyopathy, BioNTech and Genentech terminate the Phase 2 BNT122-01 trial of autogene cevumeran in resected colorectal cancer, and Alumis’ envudeucitinib misses its primary endpoint in the Phase 2b LUMUS trial in systemic lupus erythematosus: the most significant clinical trial results 4 September 2026 has to offer from across the pipeline.
This was a week split almost evenly between success and failure, with a cardiology congress supplying much of the late-stage data and sponsors releasing very different amounts of it. The standout is the first positive late-stage trial in a form of inherited heart muscle disease that has never had a medicine aimed at its underlying biology, published in full alongside its dose-limiting safety signal. Two regulatory clearances sat beside it, both in chronic conditions where existing treatment is burdensome rather than absent. Three programmes fell short, one halted outright on a survival imbalance and another reported without a single efficacy number. Here, Life Science Daily News brings you the most significant clinical trial results 4 September 2026.
Aficamten Meets Both Primary Endpoints in the First Positive Phase 3 Trial in Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced on 28 August 2026 that primary results from ACACIA-HCM, the pivotal Phase 3 trial of aficamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy, had been presented in a Hot Line session at the European Society of Cardiology Congress in Munich and published simultaneously in the New England Journal of Medicine. The trial met both dual primary endpoints at week 36, and the company’s chief medical officer calls it the first ever positive clinical trial in this form of the disease. Roughly half of all hypertrophic cardiomyopathy is non-obstructive, and Cytokinetics notes that these patients have no approved medicine directly addressing their underlying disease. Aficamten is already marketed as Myqorzo for symptomatic obstructive disease.
ACACIA-HCM randomised and treated 517 participants outside Japan on a 1:1 basis, with a significance threshold of 0.025 for each primary endpoint. Aficamten improved the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 3.0 points more than placebo (95% CI 0.5 to 5.5, p=0.021) and peak oxygen uptake by 0.67 ml/kg/min more (95% CI 0.22 to 1.1, p=0.003). These are modest absolute effects, and two ranked secondary endpoints were missed: left atrial volume index (p=0.058) and time to first cardiovascular event (p=0.678). Improvement by at least one New York Heart Association class reached 41.9 per cent against 27.8 per cent on placebo. Ejection fraction fell below 50 per cent in 10.5 per cent of the aficamten arm against 0.8 per cent on placebo, and serious adverse events occurred in 20.2 per cent against 14.7 per cent. Symptom scores fell back to placebo levels within four weeks of withdrawal. A supplemental New Drug Application is planned for the fourth quarter.
Takeda and Protagonist’s Mimrylo Approved as the First Hepcidin Mimetic for Polycythaemia Vera
Takeda announced on 28 August 2026 that the FDA had approved Mimrylo (rusfertide) for erythrocytosis in adults with polycythaemia vera, a chronic blood cancer in which overproduction of red cells thickens the blood and raises the risk of stroke, deep vein thrombosis and pulmonary embolism. The regulator described it as the first approved treatment for the condition that mimics hepcidin, the hormone governing how much iron is available to make new red cells. Rusfertide was discovered by Protagonist Therapeutics, which led development through Phase 3 before Takeda assumed the filing and took exclusive global commercialisation rights. Roughly 90,000 people in the United States have the condition.
Approval rests on the Phase 3 VERIFY study (NCT05210790), which randomised 293 adults 1:1 to Mimrylo or placebo alongside standard care over 32 weeks, starting at 19 mg subcutaneously once weekly and titrating to hold haematocrit below 45 per cent. The primary endpoint was the proportion of patients not meeting criteria for phlebotomy between weeks 20 and 32: 76.9 per cent on Mimrylo against 32.9 per cent on placebo. The label repays careful reading. It carries no restriction by line of therapy, risk category or genotype, whereas VERIFY enrolled a narrower group, patients still phlebotomy dependent despite treatment that could include hydroxyurea, interferon or ruxolitinib. Injection site reactions affected 56 per cent of treated patients and anaemia 16 per cent; the label also warns of thrombocytosis.
FDA Approves Gilead’s Bixlenvo for Virologically Suppressed Adults with HIV
This approval was announced on 27 August, one day before this edition’s coverage window opens, and was not covered in last week’s roundup. Given its clinical significance we are including it here.
Gilead Sciences announced on 27 August 2026 that the FDA had approved Bixlenvo, a once daily single tablet combining bictegravir 75 mg with lenacapavir 50 mg, for HIV in adults who are virologically suppressed. At 7 by 13 millimetres it is the smallest available single tablet regimen, and Gilead describes it as the first and only such option for most people on complex regimens who cannot take existing ones. The combination pairs a guideline recommended integrase strand transfer inhibitor with a first in class capsid inhibitor that has no cross resistance to other antiretrovirals. Treatment begins with a two day initiation period using lenacapavir separately.
Approval is supported by the Phase 3 ARTISTRY-1 (NCT05502341) and ARTISTRY-2 (NCT06333808) trials, presented in late breaker sessions at the Conference on Retroviruses and Opportunistic Infections and published in The Lancet and Lancet HIV. ARTISTRY-1 tested a switch from complex multi tablet regimens; ARTISTRY-2 compared the new tablet against Gilead’s own Biktarvy. Gilead reports comparable efficacy in maintaining virologic suppression at week 48 in both, though no figures accompany that claim, so the margin cannot be judged from the release. ARTISTRY-1 enrolled the oldest group in any registrational Phase 3 HIV treatment trial to date: median age 60 years, a median 28 years of prior treatment, resistance to nucleoside reverse transcriptase inhibitors in 67 per cent, and a baseline burden of between two and 11 tablets a day. The most common adverse reactions were headache, nausea and diarrhoea.
Eplontersen Misses Its Primary Endpoint in the Phase 3 CARDIO-TTRansform Trial in Cardiac Amyloidosis
AstraZeneca and Ionis presented full results on 28 August 2026 confirming that CARDIO-TTRansform, the largest trial yet conducted in transthyretin amyloid cardiomyopathy, did not meet its primary efficacy endpoint. The two companies had disclosed the topline miss in July; the Hot Line presentation in Munich supplied the numbers behind it. Eplontersen is a once monthly RNA targeted silencer that reduces production of transthyretin in the liver, and is already approved for hereditary transthyretin amyloid polyneuropathy. The cardiac form of the disease, caused by misfolded transthyretin depositing in heart muscle, is progressive and fatal and affects an estimated 300,000 to 500,000 people worldwide.
The double blind trial enrolled 1,432 patients with wild type or hereditary disease across 130 centres in 20 countries, randomised 1:1 to eplontersen 45 mg or placebo by subcutaneous injection every four weeks. On the composite of cardiovascular mortality and recurrent cardiovascular events there were 381 events in 210 patients on eplontersen against 392 events in 231 patients on placebo, a rate ratio of 0.89 (95% CI 0.73 to 1.09, p=0.277). Serum transthyretin was suppressed as expected, so this is not a failure of target engagement. A prespecified subgroup analysis pointed instead to background therapy: 57 per cent of participants were taking a stabiliser at baseline, and among those the drug added nothing, while among those not taking one, fewer primary endpoint events occurred and the difference reached nominal significance. That is a hypothesis rather than a finding, and the presenting investigator concluded that an unmet need remains.
BioNTech and Genentech Terminate the Phase 2 Autogene Cevumeran Trial in Resected Colorectal Cancer
BioNTech announced on 28 August 2026 that it had decided to terminate the Phase 2 BNT122-01 trial (NCT04486378) evaluating autogene cevumeran, an individualised mRNA cancer immunotherapy, as adjuvant monotherapy in patients with circulating tumour DNA positive, surgically resected high risk Stage II or Stage III colorectal cancer. The decision was taken in consultation with Genentech, which develops the therapy jointly with BioNTech, and followed a new recommendation from the trial’s independent Data Safety Monitoring Board. The comparator arm was watchful waiting, the current standard of care in this setting.
The board identified a numerical imbalance in overall survival between the arms and judged that continuing was unlikely to change the outcome. No new safety signals were identified. The sequence deserves recording plainly. The trial crossed its prespecified futility boundary in October 2025, at which point the board concluded the data were not mature enough to support reliable conclusions about efficacy, so BioNTech continued per protocol with no objection. Ten months later the same board recommended stopping. This was a deliberately hard test: an individualised mRNA therapy given without a checkpoint inhibitor in an immunologically cold tumour, unlike the Phase 3 win in melanoma reported nine days earlier. No trial data have been released. The separate Phase 2 IMcode003 study (NCT05968326) in adjuvant pancreatic cancer, which combines the therapy with checkpoint inhibition and chemotherapy, continues as planned. We have set out separately what the halt means for cancer vaccine trial design.
Alumis’ Envudeucitinib Misses Primary and Secondary Endpoints in the Phase 2b LUMUS Lupus Trial
Alumis announced on 1 September 2026 that its Phase 2b LUMUS trial of envudeucitinib in moderate to severe systemic lupus erythematosus had missed both its primary and its secondary endpoints in the overall trial population. Envudeucitinib is an oral allosteric inhibitor of tyrosine kinase 2, an enzyme sitting at the junction of the interleukin 23 and type I interferon signalling pathways. The company nonetheless intends to approach regulators about Phase 3 development in lupus on the strength of a prespecified subgroup, and remains on track to file in plaque psoriasis in the fourth quarter.
LUMUS (NCT05966480) enrolled 408 adults with moderately to severely active, autoantibody positive disease, randomised to one of three doses of envudeucitinib or to placebo for 48 weeks, with the British Isles Lupus Assessment Group based Composite Lupus Assessment at week 48 as the primary endpoint. Alumis attributes the overall miss to an unexpected under representation of patients with a high interferon gene signature, a group that typically responds better to interferon directed therapy and shows lower placebo response rates, and reports robust responses in that prespecified subgroup. No efficacy figures of any kind accompany that claim, for either the subgroup or the overall population, which makes it impossible to weigh. Pharmacodynamic data showed dose dependent pathway engagement, with maximal suppression at 40 mg twice daily. The drug was well tolerated with no new safety signals.
Looking Ahead
This week’s clinical trial results 4 September 2026 divide less neatly into wins and losses than into results reported in full and results reported barely at all. The hypertrophic cardiomyopathy data are the most likely to change practice, and they arrived with confidence intervals, two missed secondary endpoints and an ejection fraction signal all visible: modest effects, but knowable ones. The polycythaemia vera approval carries a clear comparative number alongside a label broader than the population that generated it. Against those, three announcements asked to be taken on trust: a switch regimen in HIV called comparable without saying to what degree, a lupus subgroup called robust without a single percentage, and a terminated cancer trial whose survival imbalance is characterised but not quantified. Two of those three are failures, where the case for full disclosure is strongest. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results 4 September 2026 that matter most across the global life sciences pipeline. Catch up on last week’s clinical trials roundup.
